Clinical trials: Aripiprazole, completed
Schizophrenia, Schizoaffective Disorder
Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular…
- Trial name
- CAMP (NCT00423878)
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- 28 sites in United States
- Volunteers
- 215 people
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer's Disease
Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects
The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.
- Trial name
- NCT00689559
- Testing
- AZD3480, Aripiprazole
- Where
- Sweden
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenia, Myelin Degeneration
The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia
The general objective of this interventional study is to explore the impact of long-acting arpiprazole on brain structure, in particular potential neurotrophic effects, neurogenetic and neuroprotective that could counteract the…
- Conditions
- Schizophrenia, Myelin Degeneration, Cognition Disorder
- Trial name
- NCT05322031
- Testing
- Aripiprazole
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Schizophrenia, Type 2 Diabetes Mellitus
Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
This proposal aims to use well-validated methodologies such as dual energy x-ray absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and hyperinsulinemic euglycemic clamps to characterize the…
- Trial name
- BMS (NCT00205660)
- Testing
- Stayers, Switchers
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia, Major Depressive Disorder
Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
This study will assess the helpfulness of the integrated call center in optimizing use of the Digital Medicine System in adult subjects with Schizophrenia, Major Depressive Disorder, or Bipolar Disorder taking oral aripiprazole.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT02722967
- Testing
- Aripiprazole + IEM (Ingestible Event Marker)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dissociative Disorders, Schizophrenia
Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic
We propose a prospective multicenter study, whose originality lies in the inclusion of the naive child and adolescent population.
- Trial name
- NCT02007928
- Testing
- Rispéridone, aripiprazole, olanzapine
- Where
- 14 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Schizophrenia
Aripiprazole Once-monthly in Patients With Schizophrenia
To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A…
- Trial name
- NCT01959035
- Testing
- Aripiprazole once-monthly
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of…
- Trial name
- NCT00608543
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia, Schizoaffective Disorder
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
This study will determine the efficacy of a medication switch to Aripiprazole for the treatment of schizophrenia or schizoaffective disorder in patients with moderate to high symptoms of social anxiety.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Social Anxiety Disorder
- Trial name
- NCT00177008
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Obesity, Weight Gain
Reducing Antipsychotic-Induced Weight Gain in Children With Metformin
Recent but limited short term studies have shown that Metformin can slow down weight gain in obese children and in children with psychotropic-induced weight gain, two distinct pediatric populations that are at risk for obesity…
- Conditions
- Obesity, Weight Gain, Psychotropic Induced Weight Gain
- Trial name
- GFMS (NCT01231074)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Nationwide Children's Hospital
Bipolar Disorder Mania
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder
The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.
- Trial name
- NCT00665366
- Testing
- Aripiprazole, Lithium, Valproate
- Where
- 73 sites in Austria, Czechia and 11 more
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression, Anorexia Nervosa
Therapeutic Drug Monitoring in Child and Adolescent Psychiatry
The investigators aim to analyse in adolescents with mental illness effectiveness, side effects, and serum level concentrations of antipsychotics (olanzapine and aripiprazole), antidepressants (Duloxetine, Atomoxetine) by means…
- Conditions
- Depression, Anorexia Nervosa, ADHD
- Trial name
- TDMKJP (NCT01057329)
- Testing
- Atomoxetine, Duloxetine, Olanzapine
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Tourette Syndrome
Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the safety, efficacy, tolerability and steady-state plasma trough concentration of flexible-dosed aripiprazole once-daily…
- Trial name
- NCT03487783
- Testing
- Aripiprazole Oral Solution
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia
Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
The purpose of this study is to determine whether aripiprazole augmentation is safe and effective in the treatment of clozapine-treated patients with refractory schizophrenia.
- Trial name
- NCT00328367
- Testing
- aripiprazole
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Seoul National University Hospital
Schizophrenia
A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia
To assess the pharmacokinetics and safety of aripiprazole intra-muscular (IM) depot formulation in patients with schizophrenia after repeated administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in…
- Trial name
- NCT02220712
- Testing
- OPC-14597 IMD
- Where
- 5 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Behavioral Symptoms, Autistic Disorder
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
This study will compare the effectiveness (how well the drug works) of aripiprazole with placebo (fixed dose) in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
- Trial name
- NCT00337571
- Testing
- Aripiprazole
- Where
- 31 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Switch Study of BMS-337039 in Schizophrenic Out-patients
The purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general…
- Trial name
- NCT00232687
- Testing
- Aripiprazole
- Where
- 72 sites in Austria, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch
Nautralsitic, Open-label, Single Arm, Uncontrolled Study Evaluating the Effects of Long Acting Injectable (LAI) on Phychosocial Functioning Congitive Functioning and Patient Reported Acceptability of Treatment 'Reported…
- Trial name
- ARILAI (NCT02697045)
- Testing
- Aripiprazole 400mg LAI
- Where
- 15 sites in Turkey (Türkiye)
- Volunteers
- 23 people
- Sponsor
- Abdi İbrahim Otsuka
Schizophrenia
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
- Trial name
- NCT01469039
- Testing
- ALKS 9072
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 623 people
- Sponsor
- Alkermes, Inc.
Bipolar 1 Disorder, Schizophrenia
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are currently on treatment with oral aripiprazole.
- Conditions
- Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Disorders
- Trial name
- NCT02050854
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.